Refractory

Refractories Market Projected to Reach $52.46 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
星期六, 四月 27, 2024

PUNE, India, April 26, 2024 /PRNewswire/ -- The report titled " Refractories Market by Alkalinity (Acidic & Neutral Refractories, Basic Refractories), Physical Form (Shaped Refractories, Unshaped Refractories), Manufacturing Process, Product, Application - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $35.77 billion in 2023 to reach $52.46 billion by 2030, at a CAGR of 5.62% over the forecast period.

Key Points: 
  • PUNE, India, April 26, 2024 /PRNewswire/ -- The report titled " Refractories Market by Alkalinity (Acidic & Neutral Refractories, Basic Refractories), Physical Form (Shaped Refractories, Unshaped Refractories), Manufacturing Process, Product, Application - Global Forecast 2024-2030 " is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $35.77 billion in 2023 to reach $52.46 billion by 2030, at a CAGR of 5.62% over the forecast period.
  • The key players in the Refractories Market include Krosaki Harima Corporation, RHI Magnesita GmbH, AGC Inc., Vesuvius PLC, Saint-Gobain S.A., and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Refractories Market.
  • "Dive into the Refractories Market Landscape: Explore 189 Pages of Insights, 656 Tables, and 26 Figures"

Wolfspeed Selects AIXTRON Tools to Support 200mm Production

Retrieved on: 
星期五, 五月 3, 2024

Herzogenrath, April 18, 2024 – Today, AIXTRON (FSE: AIXA) announced Wolfspeed, Inc. (NYSE: WOLF), the global leader in silicon carbide technology, has placed multiple-tool orders in Q3 and Q4 2023 to utilize AIXTRON’s G10-SiC to help further ramp production for 200mm (8-inch) silicon carbide (SiC) epitaxial wafers.

Key Points: 
  • Herzogenrath, April 18, 2024 – Today, AIXTRON (FSE: AIXA) announced Wolfspeed, Inc. (NYSE: WOLF), the global leader in silicon carbide technology, has placed multiple-tool orders in Q3 and Q4 2023 to utilize AIXTRON’s G10-SiC to help further ramp production for 200mm (8-inch) silicon carbide (SiC) epitaxial wafers.
  • “We’re pleased with the AIXTRON team’s efforts to support the expansion of our 200mm silicon carbide epitaxy process.
  • The company’s G10-SiC has proven to be a suitable, reliable tool that will support our high-volume production needs currently on the Durham campus and ultimately at our new 200mm materials factory, The John Palmour Manufacturing Center for Silicon Carbide (The JP),” said Wolfspeed Chief Technology Officer, Elif Balkas.
  • First launched in September 2022, AIXTRON’s G10-SiC has quickly become the tool of record for both 150mm and 200mm silicon carbide epitaxy.

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on: 
星期一, 十二月 11, 2023

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
  • The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
  • This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting

Retrieved on: 
星期五, 十二月 1, 2023

IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that it will present a poster titled “Selective NKCC1 Inhibitors for the Treatment of Refractory Epilepsy” at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1-5 in Orlando, FL.

Key Points: 
  • IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that it will present a poster titled “Selective NKCC1 Inhibitors for the Treatment of Refractory Epilepsy” at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1-5 in Orlando, FL.
  • “The altered expression of chloride importer NKCC1, which can lead to an imbalance in brain excitation and inhibition, is implicated in several neurodevelopmental and neurological conditions, including drug-resistant epilepsies like Mesial Temporal Lobe Epilepsy (MTLE) and Dravet syndrome,” said Annalisa Savardi, Team Leader Neuropharmacology at IAMA Therapeutics.
  • “In the upcoming presentation, preclinical data show that IAMA’s lead program IAMA-6, a small molecule targeting NKCC1 for the treatment of autism and epilepsy, effectively reduces epileptic activity in an animal model of MTLE and, in preliminary data, reduces the number of seizures in a model of Dravet syndrome.
  • “We look forward to sharing more with the healthcare providers, scientists, advocates, and other industry professionals dedicated to better outcomes for people with epilepsy at AES 2023.”

Chromite (CAS 1308-31-2) Global Market Research Report 2023: Applications, Manufacturing Methods, Patents, Pricing and Major End-Use Sectors - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 20, 2023

The "Chromite (CAS 1308-31-2) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chromite (CAS 1308-31-2) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The Chromite global market report provides a detailed overview of Chromite, covering several key points to offer valuable insights for businesses and stakeholders.
  • The report explores the description, applications, and related patterns of Chromite, allowing readers to gain a deeper understanding of this mineral.
  • Additionally, it provides insights into the current market situation, including details about Chromite manufacturers and distributors.

10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH

Retrieved on: 
星期三, 十一月 15, 2023

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
  • A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
    Session Name: 623.
  • Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
    Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
    Presentation Time: 6:00 PM - 8:00 PM, Dec. 11, 2023 (Monday, EST)
    Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
    Session Name: 623.
  • Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
    Presentation Time: 6:00 PM - 8:00 PM, Dec. 10, 2023 (Sunday, EST)
    Preliminary Safety, Pharmacological, and Efficacy Data from Patients with Relapsed or Refractory B-cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Monolith considers the cultural and social implications of new technology, without overdoing it

Retrieved on: 
星期四, 十月 26, 2023

One of the socially redeeming features of mass media has always been its communal aspect, the fact people are drawn together into a shared experience based on network programming.

Key Points: 
  • One of the socially redeeming features of mass media has always been its communal aspect, the fact people are drawn together into a shared experience based on network programming.
  • Of course, this, in the English-speaking world at least, has been driven by the desire for profit through selling advertising space to corporations.
  • Her investigation takes her across the globe and back through time to the 1980s and the Cold War.
  • We watch as she interviews people, often using ethically dubious practices, and assembles the material entirely from inside her home.

What is the monolith?

  • We never definitively find out (which some viewers will surely find annoying).
  • The obscurity with which the film represents the bricks seems to call for this kind of allegorical reading.
  • Joining Sullivan are the voices of some well-known Australian actors including Damon Herriman, Kate Box and Erik Thomson.

The strange solitude of interpersonal communication

  • The strange solitude of interpersonal communication in the global information economy underpins the whole thing, and the screen is replete with a plethora of different technologies reflecting this – talking head videos online, audio recording, editing and streaming, mobile phones, smart houses, close-ups of digital text.
  • At the same time, we watch her go about the day-to-day business of living – making food in the kitchen, eating, showering at night – her deep solitude foregrounded throughout.
  • Despite this, Monolith remains an effective fantasy-thriller, remarkably engaging given its limitations – one location, one actor (well, two, including pet turtle Ian).
  • It’s also refreshing to see a high concept Australian film, as opposed to the usual social realist and period dramas.


Ari Mattes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Refractory Materials Market size to increase by USD 6.55 billion from 2022 to 2027 | Alsey Refractories Co., Carborundum Universal Ltd., Chosun Refractories ENG Co. Ltd. and more among key companies - Technavio

Retrieved on: 
星期三, 十月 18, 2023

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The refractory materials market size is expected to grow by USD 6.55 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The refractory materials market size is expected to grow by USD 6.55 billion from 2022 to 2027.
  • However, factors such as fluctuation in the cost of refractories raw materials and high energy consumption may impede market growth.
  • View Free PDF Sample Report
    The refractory materials market for the steel industry size is estimated to grow at a CAGR of 4.27% between 2022 and 2027 with the market size forecast to increase by USD 2,152.48 million.
  • The Global Metal Matrix Composites Market size is estimated to grow at a CAGR of 7.32% between 2022 and 2027 with the market size forecast to increase by USD 163.7 million.

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

Retrieved on: 
星期四, 八月 31, 2023

NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in Houston, September 6-9, 2023. 

Key Points: 
  • NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in Houston, September 6-9, 2023.
  • Details of the SOHO poster presentations:
    Poster Title: The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies